Raymond James added Ionis Pharmaceuticals (IONS) to the firm’s Analyst Current Favorites list saying the recent pullback in the shares is unwarranted. The firm has a Strong Buy rating on the shares with a $61 price target The analyst sees “a lot of untapped value” in Ionis’ pipeline, and believes the setup for the stock over the next 12-18 months is favorable. Raymond James expects approval for Olezarsen in familial chylomicronemia syndrome later in December, “which will help transition the company to commercial.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target lowered to $62 from $65 at Piper Sandler
- Ionis Pharmaceuticals price target lowered to $77 from $82 at Wells Fargo
- Ionis Pharmaceuticals Reports Q3 2024 Financial Results
- Morning Movers: CVS Health surges and ODP sinks following Q3 results
- Ionis Pharmaceuticals announces pivotal Phase 3 trial design for ION582